TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Long-Term, Randomized, Double-Blind, Parallel Group Study of Fluticasone Furoate/GW642444 Inhalation Powder Once-Daily and Fluticasone Furoate Inhalation Powder Once-Daily in Subjects With Asthma
Brief Summary: This study will establish the safety as well as demonstrate benefit of the addition of a LABA to an ICS by utilizing an endpoint (time to first severe asthma exacerbation) that informs on both safety and efficacy.


Options:
A: Arm Label: Arm 1; Type: EXPERIMENTAL; Interventions: Drug: GW685698X 200mcg,GW685698X 200mcg and 400mcg | Intervention Type: DRUG; Name: GW685698X 200mcg,GW685698X 200mcg and 400mcg; Assigned to Arm(s): Arm 1
B: Arm Label: Fluticasone furoate/GW642444; Type: EXPERIMENTAL; Interventions: Drug: Fluticasone Furoate/GW642444 | Arm Label: fluticasone furoate; Type: EXPERIMENTAL; Interventions: Drug: Fluticasone furoate | Intervention Type: DRUG; Name: Fluticasone Furoate/GW642444; Assigned to Arm(s): Fluticasone furoate/GW642444 | Intervention Type: DRUG; Name: Fluticasone furoate; Assigned to Arm(s): fluticasone furoate
C: Arm Label: Arm 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Fluticasone propionate 100mcg, Drug: Vilanterol | Arm Label: Arm 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Fluticasone propionate 100mcg, Drug: Vilanterol | Arm Label: Arm 3; Type: ACTIVE_COMPARATOR; Interventions: Drug: Fluticasone propionate 100mcg, Drug: Vilanterol | Arm Label: Arm 4; Type: PLACEBO_COMPARATOR; Interventions: Drug: Fluticasone propionate 100mcg, Drug: Placebo | Intervention Type: DRUG; Name: Fluticasone propionate 100mcg; Assigned to Arm(s): Arm 1, Arm 2, Arm 3, Arm 4 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Arm 4 | Intervention Type: DRUG; Name: Vilanterol; Assigned to Arm(s): Arm 1, Arm 2, Arm 3
D: Arm Label: Fluticasone Furoate/Vilanterol; Type: EXPERIMENTAL; Interventions: Drug: Fluticasone Furoate/Vilanterol Inhalation Powder, Other: Placebo Inhalation Powder 2 | Arm Label: Fluticasone Furoate; Type: ACTIVE_COMPARATOR; Interventions: Drug: Fluticasone Furoate Inhalation Powder, Other: Placebo Inhalation Powder 2 | Arm Label: Fluticasone Propionate; Type: ACTIVE_COMPARATOR; Interventions: Drug: Fluticasone Propionate Inhalation Powder, Other: Placebo Inhalation Powder 1 | Intervention Type: DRUG; Name: Fluticasone Furoate/Vilanterol Inhalation Powder; Assigned to Arm(s): Fluticasone Furoate/Vilanterol | Intervention Type: DRUG; Name: Fluticasone Furoate Inhalation Powder; Assigned to Arm(s): Fluticasone Furoate | Intervention Type: DRUG; Name: Fluticasone Propionate Inhalation Powder; Assigned to Arm(s): Fluticasone Propionate | Intervention Type: OTHER; Name: Placebo Inhalation Powder 1; Assigned to Arm(s): Fluticasone Propionate | Intervention Type: OTHER; Name: Placebo Inhalation Powder 2; Assigned to Arm(s): Fluticasone Furoate, Fluticasone Furoate/Vilanterol

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Long-Term, Randomized, Double-Blind, Parallel Group Study of Fluticasone Furoate/GW642444 Inhalation Powder Once-Daily and Fluticasone Furoate Inhalation Powder Once-Daily in Subjects With Asthma
Brief Summary: This study will establish the safety as well as demonstrate benefit of the addition of a LABA to an ICS by utilizing an endpoint (time to first severe asthma exacerbation) that informs on both safety and efficacy.


Options:
A: Arm Label: Fluticasone furoate/GW642444; Type: EXPERIMENTAL; Interventions: Drug: Fluticasone Furoate/GW642444 | Arm Label: fluticasone furoate; Type: EXPERIMENTAL; Interventions: Drug: Fluticasone furoate | Intervention Type: DRUG; Name: Fluticasone Furoate/GW642444; Assigned to Arm(s): Fluticasone furoate/GW642444 | Intervention Type: DRUG; Name: Fluticasone furoate; Assigned to Arm(s): fluticasone furoate
B: Intervention Type: DRUG; Name: FLUTIFORM® (Formoterol fumarate / Fluticasone propionate); Assigned to Arm(s): N/A
C: Arm Label: Symbicort; Type: ACTIVE_COMPARATOR; Interventions: Drug: Budesonide/formoterol (SYMBICORT) pMDI | Arm Label: Budesonide; Type: ACTIVE_COMPARATOR; Interventions: Drug: Budesonide HFA pMDI | Intervention Type: DRUG; Name: Budesonide/formoterol (SYMBICORT) pMDI; Assigned to Arm(s): Symbicort | Intervention Type: DRUG; Name: Budesonide HFA pMDI; Assigned to Arm(s): Budesonide
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: budesonide/formoterol | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: budesonide | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Drug: formoterol | Intervention Type: DRUG; Name: budesonide/formoterol; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: budesonide; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: formoterol; Assigned to Arm(s): 3

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Long-Term, Randomized, Double-Blind, Parallel Group Study of Fluticasone Furoate/GW642444 Inhalation Powder Once-Daily and Fluticasone Furoate Inhalation Powder Once-Daily in Subjects With Asthma
Brief Summary: This study will establish the safety as well as demonstrate benefit of the addition of a LABA to an ICS by utilizing an endpoint (time to first severe asthma exacerbation) that informs on both safety and efficacy.


Options:
A: Arm Label: QVM149 150/50/160 µg o.d.; Type: EXPERIMENTAL; Interventions: Drug: QVM149 150/50/160 | Arm Label: QVM149 150/50/80 µg o.d.; Type: EXPERIMENTAL; Interventions: Drug: QVM149 150/50/80 | Arm Label: QMF149 150/320 µg o.d.; Type: ACTIVE_COMPARATOR; Interventions: Drug: QMF149 150/320 | Arm Label: QMF149 150/160 µg o.d.; Type: ACTIVE_COMPARATOR; Interventions: Drug: QMF149 150/160 | Arm Label: Salmeterol/fluticasone 50/500 μg b.i.d.; Type: ACTIVE_COMPARATOR; Interventions: Drug: salmeterol/fluticasone | Intervention Type: DRUG; Name: QVM149 150/50/160; Assigned to Arm(s): QVM149 150/50/160 µg o.d. | Intervention Type: DRUG; Name: QVM149 150/50/80; Assigned to Arm(s): QVM149 150/50/80 µg o.d. | Intervention Type: DRUG; Name: QMF149 150/320; Assigned to Arm(s): QMF149 150/320 µg o.d. | Intervention Type: DRUG; Name: QMF149 150/160; Assigned to Arm(s): QMF149 150/160 µg o.d. | Intervention Type: DRUG; Name: salmeterol/fluticasone; Assigned to Arm(s): Salmeterol/fluticasone 50/500 μg b.i.d.
B: Arm Label: Fluticasone furoate 50 mcg; Type: EXPERIMENTAL; Interventions: Drug: Fluticasone furoate 50mcg | Arm Label: Fluticasone propionate 100mcg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Fluticasone propionate 100mcg | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Fluticasone furoate 50mcg; Assigned to Arm(s): Fluticasone furoate 50 mcg | Intervention Type: DRUG; Name: Fluticasone propionate 100mcg; Assigned to Arm(s): Fluticasone propionate 100mcg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Fluticasone furoate/GW642444; Type: EXPERIMENTAL; Interventions: Drug: Fluticasone Furoate/GW642444 | Arm Label: fluticasone furoate; Type: EXPERIMENTAL; Interventions: Drug: Fluticasone furoate | Intervention Type: DRUG; Name: Fluticasone Furoate/GW642444; Assigned to Arm(s): Fluticasone furoate/GW642444 | Intervention Type: DRUG; Name: Fluticasone furoate; Assigned to Arm(s): fluticasone furoate
D: Arm Label: GW685698X; Type: EXPERIMENTAL; Interventions: Drug: GW685698X | Intervention Type: DRUG; Name: GW685698X; Assigned to Arm(s): GW685698X

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Placebo-Controlled Trial of D-Cycloserine for the Enhancement of Social Skills Training in Pervasive Developmental Disorders
Brief Summary: The purpose of this study is to determine the effectiveness of D-cycloserine for improving social impairment in child with pervasive developmental disorders (PDD).


Options:
A: Arm Label: D-cycloserine; Type: EXPERIMENTAL; Interventions: Drug: D-cycloserine | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: D-cycloserine; Assigned to Arm(s): D-cycloserine | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Intranasal Oxytocin (Syntocinon); Type: EXPERIMENTAL; Interventions: Drug: Intranasal Oxytocin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Intranasal Oxytocin; Assigned to Arm(s): Intranasal Oxytocin (Syntocinon) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: D-cycloserine | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: D-cycloserine; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2
D: Arm Label: Memantine; Type: EXPERIMENTAL; Interventions: Drug: Memantine | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Arm Label: Control Group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Memantine; Assigned to Arm(s): Memantine | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Placebo-Controlled Trial of D-Cycloserine for the Enhancement of Social Skills Training in Pervasive Developmental Disorders
Brief Summary: The purpose of this study is to determine the effectiveness of D-cycloserine for improving social impairment in child with pervasive developmental disorders (PDD).


Options:
A: Arm Label: Oxytocin; Type: EXPERIMENTAL; Interventions: Drug: Intranasal Oxytocin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Intranasal Oxytocin; Assigned to Arm(s): Oxytocin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Arm 1: 12 weeks of study drug then 15 weeks of placebo; Type: EXPERIMENTAL; Interventions: Drug: Oral cannabidiol 100mg/mL, Drug: Placebo | Arm Label: Arm 3: 15 weeks of placebo then 12 weeks of study drug; Type: EXPERIMENTAL; Interventions: Drug: Oral cannabidiol 100mg/mL, Drug: Placebo | Arm Label: Arm 3: 27 weeks of study drug; Type: EXPERIMENTAL; Interventions: Drug: Oral cannabidiol 100mg/mL | Intervention Type: DRUG; Name: Oral cannabidiol 100mg/mL; Assigned to Arm(s): Arm 1: 12 weeks of study drug then 15 weeks of placebo, Arm 3: 15 weeks of placebo then 12 weeks of study drug, Arm 3: 27 weeks of study drug | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Arm 1: 12 weeks of study drug then 15 weeks of placebo, Arm 3: 15 weeks of placebo then 12 weeks of study drug
C: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Divalproex Sodium; Type: EXPERIMENTAL; Interventions: Drug: Divalproex sodium | Intervention Type: DRUG; Name: Divalproex sodium; Assigned to Arm(s): Divalproex Sodium | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: D-cycloserine; Type: EXPERIMENTAL; Interventions: Drug: D-cycloserine | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: D-cycloserine; Assigned to Arm(s): D-cycloserine | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Placebo-Controlled Trial of D-Cycloserine for the Enhancement of Social Skills Training in Pervasive Developmental Disorders
Brief Summary: The purpose of this study is to determine the effectiveness of D-cycloserine for improving social impairment in child with pervasive developmental disorders (PDD).


Options:
A: Intervention Type: DRUG; Name: methylphenidate; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: guanfacine; Assigned to Arm(s): N/A
B: Arm Label: Lurasidone 20 mg; Type: EXPERIMENTAL; Interventions: Drug: Lurasidone 20 mg daily | Arm Label: Lurasidone 60 mg; Type: EXPERIMENTAL; Interventions: Drug: Lurasidone | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Lurasidone 20 mg daily; Assigned to Arm(s): Lurasidone 20 mg | Intervention Type: DRUG; Name: Lurasidone; Assigned to Arm(s): Lurasidone 60 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: RG7314; Type: EXPERIMENTAL; Interventions: Drug: RG7314 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: RG7314; Assigned to Arm(s): RG7314
D: Arm Label: D-cycloserine; Type: EXPERIMENTAL; Interventions: Drug: D-cycloserine | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: D-cycloserine; Assigned to Arm(s): D-cycloserine | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Placebo-Controlled Trial of D-Cycloserine for the Enhancement of Social Skills Training in Pervasive Developmental Disorders
Brief Summary: The purpose of this study is to determine the effectiveness of D-cycloserine for improving social impairment in child with pervasive developmental disorders (PDD).


Options:
A: Arm Label: Memantine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Memantine | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Memantine; Assigned to Arm(s): Memantine | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: D-cycloserine; Type: EXPERIMENTAL; Interventions: Drug: D-cycloserine | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: D-cycloserine; Assigned to Arm(s): D-cycloserine | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Memantine - Extended Release (ER) | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Memantine - Extended Release (ER); Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2
D: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: memantine; Type: ACTIVE_COMPARATOR; Interventions: Drug: memantine | Intervention Type: DRUG; Name: memantine; Assigned to Arm(s): memantine | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Double-blind, Double-dummy, Randomised, Comparative, Multi-centre Phase III Study on the Efficacy and Tolerability of an 8-week Oral Treatment With 9 mg Budesonide Once Daily vs. 3 mg Budesonide Three-times Daily in Patients With Active Crohn's Disease
Brief Summary: This study aims to evaluate the efficacy of 9 mg budesonide once daily (OD) versus 3 mg budesonide three-times daily (TID) for the induction of remission in Crohn's disease.


Options:
A: Arm Label: Vedolizumab; Type: EXPERIMENTAL; Interventions: Drug: vedolizumab | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: vedolizumab; Assigned to Arm(s): Vedolizumab | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo
B: Intervention Type: DRUG; Name: Certolizumab Pegol (CDP870); Assigned to Arm(s): N/A
C: Arm Label: A; Type: EXPERIMENTAL; Interventions: Drug: budesonide | Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Drug: budesonide | Intervention Type: DRUG; Name: budesonide; Assigned to Arm(s): A | Intervention Type: DRUG; Name: budesonide; Assigned to Arm(s): B
D: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: D9421-C, 9mg | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: D9421-C, 15mg | Arm Label: 3; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: D9421-C, 9mg; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: D9421-C, 15mg; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 3

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Rehabilitation of Cancer Survivors in Denmark: A Randomized Controlled Trial on the Effect of a Multi-focused Psychosocial Rehabilitation Course
Brief Summary: This randomized study evaluates the effect of a multi-focused, psychosocial 6-day residential rehabilitation course at a Danish rehabilitation centre for cancer survivors. The investigators hypothesize that individuals in the intervention group will experience better psychosocial well-being and more adaptive health behaviour changes as compared to individuals in the control group.


Options:
A: Arm Label: Exercise; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Physical exercise, Other: best supportive care | Arm Label: No exercise; Type: OTHER; Interventions: Other: best supportive care | Intervention Type: BEHAVIORAL; Name: Physical exercise; Assigned to Arm(s): Exercise | Intervention Type: OTHER; Name: best supportive care; Assigned to Arm(s): Exercise, No exercise
B: Arm Label: 1: exercise with 2 counseling types; Type: EXPERIMENTAL; Interventions: Behavioral: Experimental 1: exercise with 2 counseling types | Arm Label: 2. Usual Care - written materials; Type: OTHER; Interventions: Other: Usual Care - written materials | Intervention Type: BEHAVIORAL; Name: Experimental 1: exercise with 2 counseling types; Assigned to Arm(s): 1: exercise with 2 counseling types | Intervention Type: OTHER; Name: Usual Care - written materials; Assigned to Arm(s): 2. Usual Care - written materials
C: Arm Label: Intervention group; Type: EXPERIMENTAL; Interventions: Behavioral: Psychosocial rehabilitation course | Arm Label: Control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Psychosocial rehabilitation course; Assigned to Arm(s): Intervention group
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Yoga | Arm Label: 2; Type: OTHER; Interventions: Other: Delayed yoga classes | Intervention Type: BEHAVIORAL; Name: Yoga; Assigned to Arm(s): 1 | Intervention Type: OTHER; Name: Delayed yoga classes; Assigned to Arm(s): 2

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Rehabilitation of Cancer Survivors in Denmark: A Randomized Controlled Trial on the Effect of a Multi-focused Psychosocial Rehabilitation Course
Brief Summary: This randomized study evaluates the effect of a multi-focused, psychosocial 6-day residential rehabilitation course at a Danish rehabilitation centre for cancer survivors. The investigators hypothesize that individuals in the intervention group will experience better psychosocial well-being and more adaptive health behaviour changes as compared to individuals in the control group.


Options:
A: Arm Label: Intervention group; Type: EXPERIMENTAL; Interventions: Behavioral: Psychosocial rehabilitation course | Arm Label: Control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Psychosocial rehabilitation course; Assigned to Arm(s): Intervention group
B: Arm Label: Yoga Group A: Minimum Exposure; Type: EXPERIMENTAL; Interventions: Other: Yoga | Arm Label: Yoga Group B: Medium Exposure; Type: EXPERIMENTAL; Interventions: Other: Yoga | Arm Label: Yoga Group C: Maximum Exposure; Type: EXPERIMENTAL; Interventions: Other: Yoga | Intervention Type: OTHER; Name: Yoga; Assigned to Arm(s): Yoga Group A: Minimum Exposure, Yoga Group B: Medium Exposure, Yoga Group C: Maximum Exposure
C: Arm Label: Stressmanagement counselling; Type: OTHER; Interventions: Other: Stressmanagement | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Stressmanagement; Assigned to Arm(s): Stressmanagement counselling
D: Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Digital Health Physical Activity Intervention Group | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Digital Health Physical Activity Intervention Group; Assigned to Arm(s): Intervention

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 2, Multicenter, Double-Blind, Placebo-Controlled Comparator Study of 2 Doses of LY2140023 Versus Placebo in Patients With DSM-IV-TR Schizophrenia
Brief Summary: An inpatient/outpatient study to see if LY2140023 is better than placebo in acutely ill patients with schizophrenia.


Options:
A: Arm Label: 160 mg LY2140023; Type: EXPERIMENTAL; Interventions: Drug: LY2140023 | Arm Label: 4 mg Risperidone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Risperidone | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: 80 mg LY2140023; Type: EXPERIMENTAL; Interventions: Drug: LY2140023 | Intervention Type: DRUG; Name: Risperidone; Assigned to Arm(s): 4 mg Risperidone | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: LY2140023; Assigned to Arm(s): 160 mg LY2140023, 80 mg LY2140023
B: Intervention Type: DRUG; Name: Aripiprazole; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Risperidone; Assigned to Arm(s): N/A
C: Arm Label: 80 milligrams (mg) LY2140023, BID; Type: EXPERIMENTAL; Interventions: Drug: LY2140023 | Arm Label: 40 mg LY2140023, BID; Type: EXPERIMENTAL; Interventions: Drug: LY2140023 | Arm Label: 10 mg LY2140023, BID; Type: EXPERIMENTAL; Interventions: Drug: LY2140023 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: LY2140023; Assigned to Arm(s): 10 mg LY2140023, BID, 40 mg LY2140023, BID, 80 milligrams (mg) LY2140023, BID | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: LY2140023; Type: EXPERIMENTAL; Interventions: Drug: LY2140023 | Arm Label: Olanzapine; Type: ACTIVE_COMPARATOR; Interventions: Drug: olanzapine | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: LY2140023; Assigned to Arm(s): LY2140023 | Intervention Type: DRUG; Name: olanzapine; Assigned to Arm(s): Olanzapine | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo

Answer: A